Recent developments include the appointment of Benjamin Albert as CEO in February 2026, Q4 2025 earnings reporting with detailed key metrics, and ongoing discussions of the company's competitive positioning and financial results.

• Benjamin Albert was appointed Chief Executive Officer and Director in February 2026, having previously served as President and Chief Operating Officer [N8].
• Health Catalyst reported Q4 2025 earnings with detailed key metrics discussed in earnings transcripts and reports in March 2026 [N2][N3].
• The company lagged Q4 earnings estimates as reported in March 2026 [N4].
• Wall Street prepared for Q4 earnings with key metric estimates prior to the report [N5].
• Health Catalyst has been executing growth initiatives including platform migration and cost optimization [N3].
• The company faces intense competition from large healthcare analytics and EHR companies, impacting market dynamics [S2].

Health Catalyst's comprehensive platform and suite of analytics applications position it well to serve healthcare organizations transitioning to value-based care models. The company's focus on innovation and client support can drive adoption and retention. Leadership changes with an experienced CEO may enhance strategic execution. Cost optimization and restructuring initiatives aim to improve operational efficiency. The company's liquidity position provides a buffer to support ongoing investments and operations.

Health Catalyst operates in a highly competitive market with large, well-financed competitors that may limit its market share and pricing power. The company has incurred significant net losses and faces risks related to execution of growth initiatives, platform migration, and cost reduction plans. Macroeconomic challenges and client concentration pose risks to revenue stability. Prolonged sales cycles and potential client disruptions during platform transitions may impact financial performance. Regulatory and industry changes could also affect demand for its solutions.

Health Catalyst's moat is based on its integrated healthcare analytics platform combining data aggregation, advanced analytics applications, and tech-enabled managed services tailored to value-based care. The company's extensive client relationships, ongoing innovation, and professional services capabilities create switching costs and client dependency. However, the moat is challenged by large, well-funded competitors with established distribution networks and integrated EHR offerings, as well as niche vendors and healthcare organizations developing in-house solutions.

• Intense Competition: Health Catalyst faces competition from large healthcare analytics firms, EHR companies, niche vendors, and healthcare organizations performing their own analytics, which may impact market share and pricing.
• Execution Risks: Risks exist related to successful execution of growth initiatives, including migration to new platforms, cost reduction and restructuring plans, and maintaining high-quality client support.
• Macroeconomic and Industry Challenges: Inflation, interest rates, cuts in Medicaid and research funding, and market volatility may reduce healthcare spending and client demand for Health Catalyst's solutions.
• Client Concentration: A significant portion of revenue is derived from a limited number of clients, and loss or renegotiation of contracts could adversely affect results.
• Financial Performance and Liquidity: The company has a history of net losses and depends on liquidity and financing arrangements, including a term loan facility with floating interest rates and restrictive covenants.

• Health Catalyst, Inc. is a healthcare technology company providing data analytics, technology platforms, healthcare consulting, care management and coordination, population health management, and health information exchange solutions.
• The company operates primarily in the healthcare sector with a focus on value-based care models and analytics applications.
• Health Catalyst has a history of acquisitions including Upfront Healthcare Services, Able Health, Healthfinch, Vitalware, Twistle, ARMUS, KPI Ninja, ERS, Carevive, Lumeon, and Intraprise, expanding its platform and client base.
• Benjamin Albert was appointed CEO in February 2026, having joined the company in January 2025 through acquisition and previously serving as COO and President.
• The board of directors includes experienced executives from healthcare and technology sectors, with members having backgrounds in healthcare systems, technology companies, and investment management.
• The company reported a net loss of $177.974 million for the fiscal year ended December 31, 2025, with basic and diluted EPS of -$2.55 per share.
• As of December 31, 2025, Health Catalyst had cash and cash equivalents of $50.814 million and short-term investments of $44.918 million, with current assets of $169.307 million and current liabilities of $89.573 million, resulting in a current ratio of 1.89 and a cash ratio of 1.07.
• Health Catalyst has executed multiple workforce reductions in 2023, 2024, and 2025 to optimize cost structure and focus investments in key areas.
• The company faces intense competition from large, well-financed healthcare analytics and EHR companies such as Epic Systems, Oracle Health, Optum Analytics, and IBM, as well as niche vendors and healthcare organizations performing their own analytics.
• Health Catalyst's sales cycle for new platform clients is typically about one year, with some variability and longer cycles for newer solutions like TEMS.
• The company is executing growth initiatives including migration of clients from DOS Solution to Health Catalyst Ignite platform, which involves risks of client disruption and cost increases.
• Health Catalyst's professional services and client support are critical to client retention and renewal, requiring specialized healthcare and technical expertise.
• The company is subject to risks from macroeconomic challenges including inflation, interest rates, Medicaid and research funding cuts, and market volatility, which may impact client spending and contract renewals.
• Health Catalyst's largest three clients accounted for approximately 13.8% of revenue in 2024, indicating some client concentration risk.
• The company maintains a code of conduct and insider trading policy applicable to all employees and directors.
• Health Catalyst's board authorized a share repurchase plan in 2022, with repurchases made in 2022 and 2023 but none in 2024.
• The company has a Credit Agreement with a Term Loan Facility of up to $225 million, with covenants restricting certain actions and exposure to floating interest rates tied to SOFR plus 6.5%.
• Health Catalyst's business model centers on recurring revenue from platform subscriptions, analytics applications, and tech-enabled managed services (TEMS).
• The company emphasizes innovation and continuous development of new analytics applications to meet evolving client needs in a rapidly changing healthcare market.
• Health Catalyst's financial figures and liquidity ratios are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.